Bitcoin's price briefly exceeded the $85,000 mark on September 25, reaching $85,007.80 per coin with a 0.70% gain over the past 24 hours. Despite breaking this significant price level, the overall daily increase remained below 1%. At the time of reporting, Bitcoin was trading close to this breached price point, indicating potential stability or consolidation around this level.
Bitcoin briefly crossed $85,000 with a 0.70% gain in the past 24 hours. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 25, 2026 18:22 WIB: out of 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell today. Notable gainers include MANA (Decentraland) up 9.10% at Rp1.619, KSM (Kusama) up 8.99% at Rp84.513, and GRT (The Graph) up 8.67% at Rp479, with varying typical hold times and Pluang order activity ratios.
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
